FRANCIS OMONIYI: Open Payments
NPI 1578292140 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,625 in 120 payments from 15 companies in 2025. Trend: 2023 $861 · 2024 $2,981 · 2025 $2,625
Food & beverage: $2,516Education: $109
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 11 | $409 |
| Janssen Pharmaceuticals, Inc | 9 | $401 |
| Teva Pharmaceuticals USA, Inc. | 17 | $357 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $284 |
| Otsuka America Pharmaceutical, Inc. | 8 | $230 |
| ABBVIE INC. | 8 | $225 |
| E.R. Squibb & Sons, L.L.C. | 29 | $204 |
| Supernus Pharmaceuticals, Inc. | 10 | $137 |
| Vanda Pharmaceuticals Inc. | 4 | $104 |
| Lundbeck LLC | 4 | $81 |
Products named: INGREZZA, REXULTI, CAPLYTA, AUSTEDO XR, VRAYLAR, INVEGA SUSTENNA, COBENFY, SPRAVATO.
Industry payments across TX — which companies pay providers there.
